NUDT1 and neoplasm: miR-145 directly targets EGFR (Epidermal Growth Factor Receptor) and NUDT1 (Nudix Hydrolase 1), thereby inhibiting downstream oncogenic signaling pathways, mainly EGFR/PI3K/AKT, and suppressing tumor growth [52].